Brand-Name (Formulary) Pharmaceutical Supply

The contract pertains to the supply of brand-name pharmaceuticals for inclusion in TRICARE’s Uniform Formulary tiers, requiring contractors to provide non-FAMP pricing and comprehensive clinical-economic data to support evaluation by the Pharmacy and Therapeutics Committee. This submission is critical for determining formulary placement, pricing terms, and ongoing eligibility for TRICARE beneficiaries, ensuring that only therapeutically appropriate and cost-effective medications are integrated into the program. All bids must adhere strictly to the non-FAMP pricing framework, which mandates transparency and alignment with TRICARE’s cost-control objectives, and must include robust evidence of clinical outcomes, comparative effectiveness, and economic impact to justify inclusion. The opportunity is issued by the Defense Health Agency under the Department of Defense, with a NAICS code of 325412 for pharmaceutical and medicine manufacturing, indicating the precise regulatory and industrial scope. The deadline for responses is July 27, 2026, and performance will be centered around the 78230 zip code area, though no specific city or state is listed beyond that. As a subcontract, the award will likely be integrated into a broader supply chain or managed care arrangement under TRICARE’s pharmaceutical services framework, with no set-aside provisions indicated. Participation requires detailed compliance with TRICARE’s formulary governance processes and the ability to deliver products consistently under agreed pricing and data disclosure terms.